Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (21-30 of 308) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2023
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive NodeLaura J Esserman, Hirra Ali, Tesia McKenzie
Evidence-Based Medicine|May 3, 2014
Fifty years of age-based screening: time for a new risk-based screening approachKarla Kerlikowske, Margaret E O'Kane, Laura J Esserman
JAMA Surgery|February 22, 2023
Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-ReplyRita A Mukhtar, Christina Yau, Laura J Esserman
JAMA|April 6, 2026
Screening for Breast Cancer-ReplyLaura J Esserman, Olufunmilayo I Olopade, Martin Eklund
Cell Reports. Medicine|June 22, 2022
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage settingA Jo Chien, Beverly Kyalwazi, Laura J Esserman
JAMA|July 31, 2013
Overdiagnosis and overtreatment in cancer: an opportunity for improvementLaura J Esserman, Ian M Thompson, Brian Reid
Communications Medicine|April 3, 2023
Guiding principles for the responsible development of artificial intelligence tools for healthcareKimberly Badal, Carmen M Lee, Laura J Esserman
JAMA Oncology|February 24, 2022
Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-ReplyRita Mukhtar, W Fraser Symmans, Laura J Esserman
The Breast Journal|March 3, 2006
Breast cancer risk assessment and prevention: a framework for shared decision-making consultationsElissa M Ozanne, Jennifer R Klemp, Laura J Esserman
JAMA Oncology|December 12, 2024
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality RiskThomas J O'Keefe, Michael D Alvarado, Laura J Esserman
Pageof 31

Showing results (21-30 of 308) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2023
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive NodeLaura J Esserman, Hirra Ali, Tesia McKenzie
Evidence-Based Medicine|May 3, 2014
Fifty years of age-based screening: time for a new risk-based screening approachKarla Kerlikowske, Margaret E O'Kane, Laura J Esserman
JAMA Surgery|February 22, 2023
Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-ReplyRita A Mukhtar, Christina Yau, Laura J Esserman
JAMA|April 6, 2026
Screening for Breast Cancer-ReplyLaura J Esserman, Olufunmilayo I Olopade, Martin Eklund
Cell Reports. Medicine|June 22, 2022
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage settingA Jo Chien, Beverly Kyalwazi, Laura J Esserman
JAMA|July 31, 2013
Overdiagnosis and overtreatment in cancer: an opportunity for improvementLaura J Esserman, Ian M Thompson, Brian Reid
Communications Medicine|April 3, 2023
Guiding principles for the responsible development of artificial intelligence tools for healthcareKimberly Badal, Carmen M Lee, Laura J Esserman
JAMA Oncology|February 24, 2022
Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-ReplyRita Mukhtar, W Fraser Symmans, Laura J Esserman
The Breast Journal|March 3, 2006
Breast cancer risk assessment and prevention: a framework for shared decision-making consultationsElissa M Ozanne, Jennifer R Klemp, Laura J Esserman
JAMA Oncology|December 12, 2024
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality RiskThomas J O'Keefe, Michael D Alvarado, Laura J Esserman
Pageof 31